Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun An orally-active
synthetic retinoid , developed to overcome all-trans retinoic acid (ATRA) resistance, with potentialantineoplastic activity.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word tamibarotene.
Examples
-
The CytRx oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib.
unknown title 2011
-
CytRx is focused on advancing its oncology portfolio and currently has seven clinical trials underway and one additional clinical trial planned with its oncology drug candidates, bafetinib, tamibarotene and INNO-206.
unknown title 2011
-
CytRx is focused on advancing its oncology portfolio and currently has seven clinical trials underway and one additional clinical trial planned with its oncology drug candidates, bafetinib, tamibarotene and INNO-206.
unknown title 2011
-
CytRx's pipeline also includes tamibarotene, which it is testing in a double-blind placebo-controlled Phase 2 clinical trial in patients with non-small-cell lung cancer, and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia APL.
unknown title 2011
-
Research and development R&D expenses were $1.9 million for the second quarter of 2011 and included development expenses for the Company's programs of $0.9 million for INNO-206, $0.1 million for bafetinib and $0.3 million for tamibarotene.
unknown title 2011
-
Research and development R&D expenses were $1.9 million for the second quarter of 2011 and included development expenses for the Company's programs of $0.9 million for INNO-206, $0.1 million for bafetinib and $0.3 million for tamibarotene.
unknown title 2011
-
Cytrx's tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia
THE MEDICAL NEWS 2010
-
Cytrx's tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia
THE MEDICAL NEWS 2010
-
The patient was treated in CytRx's Phase 2 STAR-1 registration trial, which is evaluating the efficacy and safety of orally available tamibarotene as a third-line treatment for APL.
THE MEDICAL NEWS 2010
-
Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from it ...
THE MEDICAL NEWS Editors 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.